

Brentuximab vedotin : アドセトリス®

- Studies which evaluate CD30 expression level, binding and resistance, and reversibility of peripheral neuropathy

Ixazomib : ニンラーロ[®]

- Multiple myeloma studies aimed at changing standard of care and/or investigating populations with high unmet medical need
- Other hematological malignancies or patient populations in Phase I/II studies using or investigating patient selection strategies

Brigatinib : アルンブリグ®

- Studies investigating brigatinib in NSCLC, evaluation of CNS activity, rational combinations with other agents/modalities, and sequencing of ALK TKIs

Mobocertinib

- Studies exploring mobocertinib in combination with SOC agents not currently being pursued in company sponsored studies, or combination studies with agents in phase 3 or equivalent late-stage clinical development in:
 - EGFR exon 20 insertion mutated NSCLC
 - EGFR exon 20 insertion mutated solid tumors
- Studies focusing on management strategies for Adverse Events (AEs)
- Translational studies investigating the impact of baseline molecular variables on outcome and mechanisms of acquired resistance
- Studies exploring optimal sequencing of EGFR inhibitors in Exon 20 insertion mutated NSCLC
- Studies focused on testing methods, including equivalence and comparison studies, or that focus on the benefits of NGS testing

Out of Scope

- Monotherapy studies in NSCLC
- Any mobocertinib schedule and dose modification

Pevonedistat

Combination studies with emerging novel agents in Higher Risk (HR) MDS, AML:

- Newly diagnosed or relapsed HR-MDS or AML
- Transplant-eligible, newly diagnosed MDS or AML (as induction or post-transplant)
- Relapsed/refractory MDS or AML

Cabozantinib：カボメティクス®

- 固形癌における標準治療不応後の検討
- 腎細胞がんに対する効果予測因子や新規併用療法の検討
- 肝細胞がんに対する治療実態の検討
- 副作用マネジメントの検討

Niraparib：ゼジューラ®

- PARP阻害剤や白金系抗悪性腫瘍剤抵抗性克服に関する検討
- デジタルツールを用いたアドヒアランス向上や適正使用推進に関する検討
- 卵巣癌、PARP阻害剤に対する効果予測因子や新規併用療法の検討
- 固形癌における標準治療不応後の検討

研究者主導研究における重点領域（対象疾患：がん）



Panitumumab : ベクティビックス®

現在募集しておりません